RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER by A. A. Kostin, A. G. Muradyan, A. O. Tolkachev, S. V. Popov

Subjects: Get full text

Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain by Eva Tirado Mercier, Daniel Callejo Velasco, Marta Rubio Cabezas, Cristina Moretones Agut, Meritxell Granell Villalón

“…**Purpose:** To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. …”
Get full text

Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies by Tilman Todenhöfer, Arnulf Stenzl, Lorenz C. Hofbauer, Tilman D. Rachner

“…New antineoplastic drugs such as abiraterone, enzalutamide, and Radium-223 are capable of further delaying SREs in patients with advanced PC. …”
Get full text

On a data-driven mathematical model for prostate cancer bone metastasis by Zholaman Bektemessov, Laurence Cherfils, Cyrille Allery, Julien Berger, Elisa Serafini, Eleonora Dondossola, Stefano Casarin

“…While treatment with the radioactive isotope radium-223 ($ ^{223} $Ra) has shown promising results, there remains room for therapy optimization. …”
Get full text